VolitionRX Limited Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VNRX, updated each market day.
VNRX AI Sentiment
AI sees no strong directional signal for VolitionRX Limited Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About VolitionRX Limited Common Stock
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Sector
Exchange
Market Cap
$23,371,462
Cap Tier
Employees
75
Headquarters
HENDERSON, NV
Listed Since
April 25, 2007
Website
VNRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VNRX Volatility
VolitionRX Limited Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
